TEM Tempus AI Inc

WHALE ALERT 🐳 $1.8 Million order for the January 15th $TEM 115 calls. 3,120 contracts @ 5.70 Currently trading at 80.

$TEM If there were a Guinness World Record for the person with the world's worst luck, I could have easily won that.

$TEM once shorts finish covering we gonna dump probably around 10 dollars. Still waitin for that 69 gap close. Daddy more patient then these wanna be gamblers.

$TEM got 84 , could dip to 82 and watch for a bounce there or break of 84 to 85 and 88 $SDGR strong day to 33, see if 32 can hold, better 32.50, for amove to 35 and 36.50 $AAOX swing from 12 got 13.85, see if 13.50 holds for 15 $MRNA had 200 res then broke to 205.77, if 200 canhold it can kepe on to 205 and 210

$TEM Here is my analysis: today will close at about 72ish, tomorrow the range will be 73 to 70ish, and Thursday it might go to 78ish.

$TEM Healthcare is the beast! Democrats who are champions of healthcare and clinical research will be back in charge here shortly…You can sell your shares if you want to…$250 easily…

$TEM Tempus AI is building one of the most compelling growth platforms in healthcare, combining clinical data, diagnostics and artificial intelligence to make medicine smarter and more personalized. Its expanding data network, growing testing business and deep relationships across healthcare create powerful long-term advantages. As more hospitals, physicians and pharmaceutical companies use Tempus, the platform can become increasingly valuable and difficult to replicate. If execution remains strong, TEM has the potential to compound growth for years and emerge as one of the defining healthcare technology companies of the AI era ahead.

$TEM TEMPUS AI — THE TIME IS NOW Since October 2025 TEMP has faced heavy corporate short selling while retail traders have added pressure by flipping for small gains instead of holding for larger gains. That activity brought TEMP to a 52-week low of $40.77 on July 28 2026. On Friday September 25 2026 TEMP closed at $85.01 — up more than 108% in roughly 8½ weeks. Think of TEMP as a rubber ball held underwater. Corporate short sellers and trading activity are holding it down. But TEMP’s fundamentals are accelerating at a rapid pace building the force that will pop that ball right out of the water. On September 24 2026 Zacks published an article recommending three AI-powered medical stocks to strengthen your portfolio: Intuitive Surgical $405.18 Thermo Fisher Scientific $675 and Tempus AI $85.01. Zacks expects TEMP’s 2027 earnings growth to exceed 100%. TEMP has climbed more than 108% from $40.77 to $85.01 while the business continues gaining momentum. $600+ someday? Very possible.

$TEM Moderna Stock Jumps 10%+. Its MRNA Cancer Vaccine Is Getting Ready for Its Next Big Test. TEM will move tomorrow..

$TEM I just re-shared a post I made on July 21 regarding my view on Tempus and why I was aggressively buying shares at that time. Tempus is up 75% since that post, however I believe it is still very early days and Tempus has a very long runway of growth. I expect we will see accelerating revenue growth in their data and applications business, as well as the diagnostic segment as MRD revenue surges in the near future. The opportunity for the application of AI within healthcare is still very underappreciated but I am now starting to see real traction. I previously mentioned the hidden value within $TEM which is worth paying close attention to, particularly when it comes to their AI applications segment. I have a very large position and will continue to buy more shares on any weakness as I believe Tempus could 10X in value over the next decade if they continue to execute well. Tempus will likely become one of the most important companies in healthcare.

$TEM FOLLOW THE MONEY TEM INSTITUTIONAL BUYERS April 1, 2026 through September 30, 2026 Goldman Sachs — +2,480,000 shares Citadel Advisors — +1,910,000 shares Morgan Stanley — +1,570,000 shares Bank of America — +1,500,000 shares Norges Bank — +975,000 shares Franklin Resources — +771,000 shares Capital Impact Advisors — +771,000 shares NEW POSITION Jane Street — +760,000 shares Susquehanna — +636,000 shares Contrarius Group — +555,000 shares NEW POSITION ARK Investment Management — +415,000 shares Clear Street — +390,000 shares Legal & General — +375,000 shares State Street — +198,000 shares Geode Capital — +153,000 shares Vanguard Portfolio Management — +234,000 shares Vanguard Capital Management — +69,000 shares JPMorgan — +54,000 shares These increases are based on the institutional positions reported for the period, with the latest Q2 13F filings disclosed through September.

$TEM: Bullish Right Angle Descending Megaphone break out and measured move price target attainment.

$TEM A few minutes ago a portfolio manager was on CNBC saying he bought $NTRA at $355 because of his belief that AI will reshape healthcare. He is right, however I would have advised him to buy the stock years ago. About an hour earlier, the CEO of $GH was on CNBC discussing liquid biopsy, specifically how MRD is becoming the new standard of care. This was news to the CNBC moderators, but many of us understood this years ago. $TEM is the company best positioned to apply AI to healthcare and transform the industry. Many of us here have done the work and understand this, therefore we will buy $TEM shares now. In a couple years you will see portfolio managers on CNBC saying they love the company and are buying it - but they’ll be paying over $200/share. You need to do your DD and if you decide to invest, do it with conviction and be early. Sophisticated retail investors can outperform the “professionals” on CNBC. They are always late to identify great companies.

$TEM they taking this to the slaughter house today Didn’t see any news as to why Just profit taking/pull back?? Or anyone see anything else

$TEM Let them play the games all they want. It will be $250 here shortly. Guaranteed! 📌this post. Desperate shorts

$TEM this stock is insane. Just dumped $6 and will probably make it all back and close green before the end of the day

$TEM this company is the future in medicine. Very much needed. The management team must be thinkers and I Bbelive they are. Innvators. 100 plus soon and on to a gusher, bam !

$TEM In my opinion a few years from now many people will look back with regret that they weren’t buying $TEM agressively when it was under $100/share. It is still undervalued. I bought $NTRA at $40. When it was trading at $100-$150 many people were saying it was expensive/overvalued. Same scenario for $PSNL and$GH. If you have a deep understanding of these businesses and how AI is completely reshaping healthcare, you will realize that these are very early days for $TEM. I view it almost as a startup..

$TEM going to $100. TEM has a huge moat. People are just coming around to the idea that it’s not so easy to build what they built and it’s worth a lot. “We had to enter into legal agreements, have BAAs in place, build pipes, ingest the data, harmonize, structure that data so that it's usable in a longitudinal format, match it to molecular data at scale, match it to digital pathology slides, the radiology scans, then build tools around that data because it's -- otherwise, it's just 500 petabytes of useless data. So we've just done all that. And if you look at it, everyone who's tried to launch a data business, which is most of our major competitors, if you look at the launch of their data business, it's 5, 6, 7 years old, have just had no traction basically. And we continue to have significant traction. So in terms of our immediate cohort, the people like us that have rich molecular data, I think we've just outpaced them dramatically.”

A lot of eyes on $TEM as trying to emerge from IPO base. Think we need over all market to push for this to run, but guess we’ll see.